Nguyen M H, Yu V L, Morris A J, McDermott L, Wagener M W, Harrell L, Snydman D R
Department of Medicine, Veterans Administration Hospital and University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Clin Infect Dis. 2000 Jun;30(6):870-6. doi: 10.1086/313805. Epub 2000 Jun 13.
There is debate regarding the correlation between in vitro susceptibility testing and clinical response to therapy for Bacteroides bacteremia. We conducted a prospective multicenter observational study of 128 patients with bacteroides bacteremia. Outcome was correlated with results of in vitro susceptibility testing of Bacteroides isolates recovered from blood and/or nonblood sites, determined with use of 3 end points: mortality at 30 days, clinical response (cure vs. failure), and microbiological response (eradication vs. persistence). The mortality rate among patients who received inactive therapy (45%) was higher than among patients who received active therapy (16%; P=.04). Clinical failure (82%) and microbiological persistence (42%) were higher for patients who received inactive therapy than for patients who received active therapy (22% and 12%, respectively; P=.0002 and.06, respectively). In vitro activity of agents directed at Bacteroides species reliably predicts outcome: the specificity was 97%, and positive predictive value was 82%. Antimicrobial susceptibility testing may be indicated for patients whose blood specimens yield Bacteroides species.
关于拟杆菌属菌血症的体外药敏试验与临床治疗反应之间的相关性存在争议。我们对128例拟杆菌属菌血症患者进行了一项前瞻性多中心观察性研究。结果与从血液和/或非血液部位分离出的拟杆菌属菌株的体外药敏试验结果相关,采用3个终点指标进行测定:30天死亡率、临床反应(治愈与失败)和微生物学反应(根除与持续存在)。接受无效治疗的患者死亡率(45%)高于接受有效治疗的患者(16%;P = 0.04)。接受无效治疗的患者临床失败率(82%)和微生物学持续存在率(42%)高于接受有效治疗的患者(分别为22%和12%;P分别为0.0002和0.06)。针对拟杆菌属菌种的药物体外活性可可靠地预测结果:特异性为97%,阳性预测值为82%。对于血液标本分离出拟杆菌属菌种的患者,可能需要进行抗菌药敏试验。